1 |
A. Verrotti, C. Salladini, G. Di Marco, F. Pisciella and F. Chiarelli, Extended-release formulations in epilepsy, J. Child. Neurol., 22, 419-26 (2007)
DOI
|
2 |
E. Spina, Carbamazepine: chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic Drugs. 5th ed. R.H. Levy, R.J. Mattson, B.S. Meldrum and E. Perucca, eds. Baltimore, U.S.A, pp. 236-46 (2002)
|
3 |
J. Moreno, A. Belmont, O. Jaimes, J.A. Santos, G. Lopez and M.G. Campos, Pharmacokinetics study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment, Arch. Med. Res., 35, 168-71 (2004)
DOI
ScienceOn
|
4 |
M. Bialer, L. Arcavi, S. Sussan, A. Volosov, A. Yacobi and D. Moros, Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine, Epilepsy Res., 32, 371-8 (1998)
DOI
ScienceOn
|
5 |
J.K. Pandit, S. Singh and M.S. Muthu, Controlled release formulations in neurology practice, Ann. Indian Acad. Neurol., 9, 207-16 (2006)
DOI
|
6 |
S. Dutta, Y. Qiu, E. Samara, G. Cao and G.R. Granneman, Once-a day extended-release dosage form of diavalproex sodium III: Devalopment and validation of a level a in vitro-in vivo correlation (IVIVC), J. Pharm. Sci., 94, 1949-56 (2005)
DOI
ScienceOn
|
7 |
S. Hayes, A.Dunne, T. Smart and J. Davis, Interpretation and optimization of the dissolution specifications for a modified release product with an in vitro-in vivo correlation (IVIVC), J. Pharm. Sci., 93, 571-81 (2004)
DOI
ScienceOn
|
8 |
Korean Guideline for Bioequivalence Test. Korea Food and Drug Administration, (2005)
|
9 |
KW. Sommerville. Bioequivalence in development of antiepileptic drugs, Epilepsy Res., 68, 82-4 (2006)
DOI
ScienceOn
|
10 |
M. Bialer, Extended-release formulations for the treatment of epilepsy CNS, Drugs, 21, 765-74 (2007)
|
11 |
J.J.I. Tamimi, I.I Salem, S.M. Alam, Q. Zaman and R. Dham, Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers, Biopharm. Drug Dispos., 26, 335-9 (2005)
DOI
ScienceOn
|
12 |
F. Bugamelli, C. Sabbioni, R. Mandrioli, E. Kenndler, F. Albani and M.A. Raggi, Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction, Anal. Chim. Acta., 472, 1-10 (2002)
DOI
ScienceOn
|
13 |
Prescribing information . Novartis Pharmaceuticals Canada Inc., (2006)
|
14 |
A. Marzo, L. Dal Bo, A. Rusca and P. Zini, Bioequivalence of ticlopidine hydrochloride administered in single dose to healthy volunteers, Pharmacol. Res., 46, 401-7 (2002)
DOI
ScienceOn
|
15 |
R. Mandrioli, F. Albani, G. Casamenti, C. Sabbioni and M.A. Raggi, Simultaneous high-performance liquid chromatography determination of carbamazepine and five of its metabolites in plasma of epileptic patients, J. Chromatogr. B, 762, 109-16 (2001)
DOI
ScienceOn
|
16 |
J.A. Cramer, R.H. Mattson, M.L. Prevey and R.D. Scheyer, Ouellette, V.L. How often is medication taken as prescribed? A novel assessment technique, JAMA, 261, 3273-7 (1989)
DOI
|
17 |
P. Pienimaki, S. Fuchs, J. Isojarvi and K. Vahakangas, Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography, J. Chromatogr. B, 673, 97-105 (1995)
DOI
ScienceOn
|